JUL 8 2026
Vera Therapeutics, Inc. — Trutakna (atacicept-vymj) $VERA
for primary IgA nephropathy
FDA granted accelerated approval to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy.
About
IgA nephropathy is a kidney disease where the immune system causes inflammation in the kidney's filtering units, which can also damage other major organs. Trutakna is a lab-made protein that works by binding to and neutralizing two specific immune system signals. This may reduce the underlying immune activity that drives the kidney inflammation and organ damage.
Drug Watch — recent news on Trutakna
- The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA Approval - Learn Why - simplywall.st
- Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch - finance.yahoo.com
- Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)? - finance.yahoo.com
- Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced? - simplywall.st
- Trutakna Approved to Reduce Proteinuria in Primary IgA Nephropathy - Medical Professionals Reference